One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp–derived measures of β-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). β-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09–2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: −0.8 ± 0.1 and −0.7 ± 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference −4.6 kg, P < 0.0001). β-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves β-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, β-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Obviously, patients treated with exenatide showed a greater improvement in acute -cell function, which is considered to be the result of binding to the -cell GLP-1 receptor (13).”
BackgroundResultKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 2×
“3 ype 2 diabetes mellitus is characterized by beta-cell dysfunction against a background of obesity-related insulin resistance (1).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies also showed amelioration of surrogate measures of beta-cell function (4-6; 8).”
BackgroundResultInfluentialBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Cited by
Items 101–200 of 388
Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., et al. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12293 · Cited by 58
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 64
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
“2009 [33] N, V, D EX10BID (36) Insulin (33) Met 52 58.”
Li, R., Xu, W., Luo, S., Xu, H., Tong, G., Zeng, L., Zhu, D., & Weng, J. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0792-2 · Cited by 59
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01428.x · Cited by 57
Aston-Mourney, K., Hull, R. L., Zraika, S., Udayasankar, J., Subramanian, S. L., & Kahn, S. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2143-3 · Cited by 56
“This observation is comparable to findings from clinical studies which show a beneficial effect on glycaemic control during active treatment [15–17], but no persistent glucose-lowering benefit of treatment after withdrawal of the drug, consistent with a lack of clinically significant improvement of beta cell mass [ 45…”
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-013-0172-6 · Cited by 65
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
Lin, E., Liang, Z., Frediani, J. K., Davis, S. S., Sweeney, J. F., Ziegler, T. R., Phillips, L. S., & Gletsu-Miller, N. A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00405.2010 · Cited by 57
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
Guyton, J., Jeon, M., & Brooks, A. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz179 · Cited by 55
Jinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., Miyamoto, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Journal of Diabetes Research · doi:10.1155/2015/706416 · Cited by 55
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Erpeldinger, S., Rehman, M. B., Berkhout, C., Pigache, C., Zerbib, Y., Regnault, F., Guérin, E., Supper, I., Cornu, C., Kassaï, B., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0120-z · Cited by 55
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_3 · Cited by 62
“In a 1-year study with exenatide, however, the improvements of the above-mentioned beta-cell function parameters were no longer present following a washout period of 12 weeks (Bunck et al. 2009).”
BackgroundHope vs hype: where are we in type 1 diabetes?
Skyler, J. S. (2018) · Diabetologia · doi:10.1007/s00125-017-4530-x · Cited by 51
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50
Basal Insulin Use With GLP-1 Receptor Agonists
Anderson, S. L., & Trujillo, J. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.152 · Cited by 58
Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes
Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01417.x · Cited by 49
Derosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0278 · Cited by 47
Esposito, K., Mosca, C., Brancario, C., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.590127 · Cited by 47
Beeler, N., Riederer, B. M., Waeber, G., & Abderrahmani, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.006 · Cited by 52
van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Self-citationType 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
Harrison, L. B., Mora, P. F., Clark, G. O., & Lingvay, I. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318279b7d6 · Cited by 46
Gurney, K., MacConell, L., Malloy, J., Zhou, M., & Kolterman, O. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s77290 · Cited by 45
Self-citationAcute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
López-Ruiz, A., Peso-Gilsanz, C., Meoro-Avilés, A., Soriano-Palao, J., Andreu, A., Cabezuelo, J., & Arias, J. L. (2010) · Pharmacy World & Science · doi:10.1007/s11096-010-9423-8 · Cited by 44
“Other investigations have also shown the existence of continuous nausea and vomiting in patients under treatment with exenatide, but the treatment was not changed (mean HbA1c 1.9% of total hemoglobin, body weight loss of 3.8 kg) [1, 7 ]. Interestingly, renal impairment in patients under treatment with exenatide has be…”
BackgroundInfluentialDavidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“However, this effect was absent after 4-weeks of being off therapy [51].”
BackgroundPractical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care
Reid, T. S. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.148 · Cited by 43
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Update on Insulin Therapy for Type 2 Diabetes
Donner, T. W., & Muñoz, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2202 · Cited by 49
Trevaskis, J. L., Mack, C. M., Sun, C., Soares, C. J., D’Souza, L. J., Levy, O. E., Lewis, D. Y., Jodka, C. M., Tatarkiewicz, K., Gedulin, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078154 · Cited by 41
Gudipaty, L., Rosenfeld, N. K., Fuller, C. S., Gallop, R., Schutta, M. H., & Rickels, M. R. (2014) · Diabetes Care · doi:10.2337/dc14-0398 · Cited by 41
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Insulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Gurkan, E., Tarkun, I., Sahin, T., Cetinarslan, B., & Canturk, Z. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.046 · Cited by 38
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Robles, G. I., & Singh‐Franco, D. (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3321 · Cited by 46
“Compared with placebo, EXE significantly slowed gastric emptying (T 50 ) for solid and liquid meals (solid T 50 , 90% confidence interval [CI]; placebo, 60 [50–70] min; EXE 5 μg, 111 [94–132] min; EXE 10 μg, 169 [143–201] min; liquid T 50 ; placebo, 34 [25–46] min; EXE 5 μg, 87 [65–117] min; EXE 10 μg, 114 [85–154] mi…”
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 46
“In addition to weight reduction, there was also a reduction in total body fat mass and truncal fat mass compared to the use of glargine [42].”
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
Zheng, S., Zhang, Y., Long, T., Lu, J., Liu, X., Yan, J., Chen, L., Gong, Y., & Wang, F. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.06.003 · Cited by 45
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 38
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Unger, J. R., & Parkin, C. G. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0013-5 · Cited by 38
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases
Nguyen, T. T. B., Jin, Y. Y., Chung, H.-J., & Hong, S.-T. (2017) · Molecules · doi:10.3390/molecules22101795 · Cited by 37
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 43
Gupta, A., Jelinek, H. F., & Al-Aubaidy, H. A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.09.003 · Cited by 40
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
Gallwitz, B., KAZDA, C. M., Kraus, P., Nicolay, C., & Schernthaner, G. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0319-4 · Cited by 39
Armato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35
Giugliano, D., Maiorino, M., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02619.x · Cited by 36
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Janardhan, S., & Sastry, G. N. (2014) · Current Drug Targets · doi:10.2174/1389450115666140311102638 · Cited by 39
Derosa, G., Carbone, A., D'Angelo, A., Querci, F., Fogari, E., Cicero, A. F. G., & Maffioli, P. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8175 · Cited by 35
Time for Testing Incretin Therapies in Early Type 1 Diabetes?
Bosi, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2741 · Cited by 34
“4-fold higher -cell function at 1 yr compared with those receiving insulin (9).”
BackgroundAnyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., & Idris, I. (2016) · Heart · doi:10.1136/heartjnl-2015-309164 · Cited by 34
Liraglutide for the treatment of type 2 diabetes
Shyangdan, D., Cummins, E., Royle, P., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1-09 · Cited by 34
Mittendorf, T., Smith‐Palmer, J., Timlin, L., Happich, M., & Goodall, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01099.x · Cited by 38
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Pinkney, J. H. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7313 · Cited by 32
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31
Blonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
Aguilar, R. B. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.008 · Cited by 34
Early Insulinization to Prevent Diabetes Progression
Raz, I., & Mosenzon, O. (2013) · Diabetes Care · doi:10.2337/dcs13-2014 · Cited by 35
“Glucagon-like peptide (GLP)-1 analogs were shown to have a potential b-cell–protective effect (18,19).”
BackgroundWang, Y., Li, L., Yang, M., Liu, H., Boden, G., & Yang, G. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01436.x · Cited by 30
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
Ridge, T., Moretto, T., MacConell, L., Pencek, R., Han, J., Schulteis, C. T., & Porter, L. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01639.x · Cited by 29
LEVIN, P. A., Wei, W., Wang, L., Pan, C., Douglas, D. J., & Başer, O. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.654850 · Cited by 29
Backeström, A., Papadopoulos, K. I., Eriksson, S., Olsson, T., Andersson, M., Blennow, K., Zetterberg, H., Nyberg, L. H., & Rolandsson, O. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247753 · Cited by 32
“Memory function was tested under two metabolic conditions: a hyperglycaemic clamp [29,30] and a placebo clamp (saline infusion).”
MethodDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1301 · Cited by 29
Ankarfeldt, M., Adalsteinsson, E., Groenwold, R., Ali, M. S., & Klungel, O. (2016) · Clinical Epidemiology · doi:10.2147/clep.s121991 · Cited by 25
Scheen, A. J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.10.007 · Cited by 31
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
“54 After 4 weeks of discontinuation of both treatment groups, however, measures of b -cell function returned to pretreatment levels.”
van Raalte, D. H., Bunck, M. C. M., Smits, M. M., Hoekstra, T., Cornér, A., Diamant, M., Eliasson, B., Marja-RiittaTaskinen, Heine, R. J., Smith, U., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0286 · Cited by 31
Self-citationKraan, T. C. T. M. V. D. P., Chen, W. J. Y., Bunck, M. C. M., van Raalte, D. H., van der Zijl, N. J., van Genugten, R. E., van Bloemendaal, L., Baggen, J. M. C., Serné, E. H., Diamant, M., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0096-y · Cited by 34
Self-citationPreumont, V., Hermans, M. P., Brichard, S. M., & Buysschaert, M. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.02.001 · Cited by 29
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Shin, M.-S., Yu, J. H., Jung, C. H., Hwang, J. Y., Lee, W. J., Kim, M., & Park, J. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0144 · Cited by 26
Li, W.-X., Gou, J.-F., Tian, J.-H., Yan, X., & Yang, L. (2010) · Current Therapeutic Research · doi:10.1016/j.curtheres.2010.08.003 · Cited by 27
Basal Insulin Treatment in Type 2 Diabetes
Hedrington, M. S., Pulliam, L., & Davis, S. N. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0062 · Cited by 28
Yin, T.-T., Bi, Y., Li, P., Shen, S.-M., Wang, W.-M., Jiang, C., Gao, C.-X., Wang, Y., Gao, L.-J., Zhu, D.-L., et al. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0295-6 · Cited by 26
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70006-3 · Cited by 27
Self-citationEmerging role of GLP-1 receptor agonists in the treatment of obesity
Neff, L. M. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s6816 · Cited by 36
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
The potential of incretin-based therapies in type 1 diabetes
Suen, C. S., & Burn, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.017 · Cited by 30
Moors, C. C. M., van der Zijl, N. J., Diamant, M., Blaak, E. E., & Goossens, G. H. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.123 · Cited by 28
Self-citationHall, G., McMahon, A., Dain, M., Wang, E., & Home, P. (2013) · Diabetic Medicine · doi:10.1111/dme.12137 · Cited by 29
Derosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., D’Angelo, A., Cicero, A. F. G., & Maffioli, P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.734499 · Cited by 28
Derosa, G., Cicero, A. F. G., Franzetti, I., Querci, F., Carbone, A., Ciccarelli, L., D’Angelo, A., Fogari, E., & Maffioli, P. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0300 · Cited by 27
Diabetic gastroparesis: Therapeutic options
Alam, U., Asghar, O., & Malik, R. A. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0010-8 · Cited by 27
Preservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Derosa, G., Carbone, A., D’Angelo, A., Querci, F., Fogari, E., Cicero, A. F. G., & Maffioli, P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.730519 · Cited by 28
Exenatide Use in the Management of Type 2 Diabetes Mellitus
Kyriacou, A., & Ahmed, A. B. (2010) · Pharmaceuticals · doi:10.3390/ph3082554 · Cited by 28
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Dicembrini, I., Pala, L., & Rotella, C. M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/898913 · Cited by 26
Baser, O., Wei, W.-H., Baser, E., & Xie, L. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.605818 · Cited by 30
Metadata
- Authors
- Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Heine, R. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Department of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg, Sweden;
- Amylin Pharmaceuticals, San Diego, California;
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;
- Eli Lilly (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-05
- Volume
- 32
- Issue
- 5
- Pages
- 762-768
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2671094
- OpenAlex
- W2148798434
- Cited by
- 388
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 16 · 2016: 19 · 2015: 24 · 2014: 34 · 2013: 40 · 2012: 44
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, beta-cell function, metformin, glycemic control, HbA1c, body weight, C-peptide secretion, drug discontinuation, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Insulin Secretion, Arginine, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Kinetics, Male, Metformin, Middle Aged, Peptides, Venoms, Body Mass Index, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.